Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A; Costa Rican Vaccine Trial Group..

J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62. doi: 10.1093/jnci/djq384. Epub 2010 Oct 13.

2.

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.

De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A.

Vaccine. 2010 Aug 31;28(38):6247-55. doi: 10.1016/j.vaccine.2010.07.007. Epub 2010 Jul 17.

PMID:
20643092
3.

Immune responses to human papilloma viruses.

Stanley MA.

Indian J Med Res. 2009 Sep;130(3):266-76. Review.

PMID:
19901436
4.

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.

Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N.

J Immunol. 2009 Nov 15;183(10):6186-97. doi: 10.4049/jimmunol.0901474. Epub 2009 Oct 28.

5.

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group..

Hum Vaccin. 2009 Oct;5(10):705-19. Epub 2009 Oct 14.

PMID:
19684472
6.

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine.

Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, Weiss NS, Koutsky LA.

Vaccine. 2009 Sep 18;27(41):5612-9. doi: 10.1016/j.vaccine.2009.07.027. Epub 2009 Jul 30.

7.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group..

Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum in: Lancet. 2010 Sep 25;376(9746):1054.

PMID:
19586656
8.

Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

Schiller JT, Lowy DR.

J Infect Dis. 2009 Jul 15;200(2):166-71. doi: 10.1086/599988. No abstract available.

9.

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.

Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, Dubin G; HPV Study Group for Adult Women..

Vaccine. 2009 Jan 22;27(4):581-7. doi: 10.1016/j.vaccine.2008.10.088. Epub 2008 Nov 18.

PMID:
19022320
10.

New quadrivalent HPV vaccine developments.

Tovar JM, Bazaldua OV.

Postgrad Med. 2008 Nov;120(4):14-6. doi: 10.3810/pgm.2008.11.1929. Review.

PMID:
19020361
11.
12.

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E.

Vaccine. 2008 Dec 9;26(52):6844-51. doi: 10.1016/j.vaccine.2008.09.073. Epub 2008 Oct 16.

PMID:
18930097
13.

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.

Schiller JT, Castellsagué X, Villa LL, Hildesheim A.

Vaccine. 2008 Aug 19;26 Suppl 10:K53-61. doi: 10.1016/j.vaccine.2008.06.002. Review.

14.

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N.

Vaccine. 2008 Aug 19;26 Suppl 10:K1-16. doi: 10.1016/j.vaccine.2008.05.064. Review.

PMID:
18847553
15.

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.

Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T.

Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049.

PMID:
18845199
16.

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature.

Schwarz TF, Leo O.

Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S1-10. doi: 10.1016/j.ygyno.2008.05.036. Epub 2008 Jul 24.

PMID:
18653222
17.

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Zeng W, Jackson DC, Roden RB.

Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5850-5. doi: 10.1073/pnas.0800868105. Epub 2008 Apr 14.

18.
19.

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.

FUTURE II Study Group..

J Infect Dis. 2007 Nov 15;196(10):1438-46. Epub 2007 Oct 31.

PMID:
18008221
20.

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

Garçon N, Chomez P, Van Mechelen M.

Expert Rev Vaccines. 2007 Oct;6(5):723-39. Review.

PMID:
17931153

Supplemental Content

Support Center